Clinical trials: Disorders of Breast
Breast Cancer, Breast Neoplasms
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with trastuzumab (Herceptin) and in combination with trastuzumab and paclitaxel.
- Trial name
- NCT01042925
- Testing
- XL147 (SAR245408), trastuzumab, paclitaxel
- Where
- 9 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Sanofi
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Micrima MARIA Data Collection for Machine Learning Study
The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues.
- Trial name
- NCT04894955
- Testing
- MARIA
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Micrima, Ltd.
Triple Negative Breast Cancer
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H…
- Trial name
- NCT03562637
- Testing
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 575 people
- Sponsor
- OBI Pharma, Inc
Metastatic Breast Cancer (MBC)
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer.
- Trial name
- CTC-EXPRESS (NCT06833853)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Menarini Silicon Biosystems, INC
Breast Cancer, Endometrial Cancer
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this "roll-over" study if they had exhibited clinical benefit from treatment and wished to continue on treatment.
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00190697
- Testing
- arzoxifene
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Breast Cancer
Food Effect Study of D-0502 Tablet in Healthy Volunteers
This is an open label, randomized, balanced, single dose, two-treatment (fed vs. fasting), two-period, two-sequence crossover study of postmenopausal female healthy subjects.
- Trial name
- NCT03810625
- Testing
- D-0502
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Breast Cancer
Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues
The purpose of this study is the identification and classification of human tissues and cytology specimens and elements therein.
- Trial name
- NCT00978276
- Sponsor
- Applied Spectral Imaging Ltd.
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER I (NCT00305448)
- Testing
- Fulvestrant
- Where
- 35 sites in Japan
- Volunteers
- 143 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
- Trial name
- NCT01427933
- Testing
- Ramucirumab (IMC-1121B), Eribulin
- Where
- 52 sites in United States
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose…
- Trial name
- NCT04541108
- Testing
- Rilvegostomig, Volrustomig, Sabestomig
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Presage Biosciences
Breast Cancer
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants.
- Trial name
- NCT00800436
- Testing
- Herceptin
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and…
- Trial name
- NCT06513364
- Testing
- WH002, paclitaxel injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Breast Cancer
The ABC Study: Assessment of Breast Density Classification
The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues.
- Trial name
- NCT04882306
- Testing
- Bilateral MARIA scan
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Micrima, Ltd.
Breast Cancer, Cancer
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers.
- Trial name
- NCT04274933
- Testing
- Venetoclax, Capecitabine
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Breast Cancer, Gastric Cancer
Safety Study of MGAH22 in HER2-positive Carcinomas
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer.
- Trial name
- NCT01148849
- Testing
- margetuximab
- Where
- 3 sites in United States, South Korea
- Volunteers
- 66 people
- Sponsor
- MacroGenics
Breast Cancer
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
The purposes of this study are : to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and to determine the…
- Trial name
- NCT01006785
- Testing
- DLBS1425
- Where
- 3 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- Dexa Medica Group
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.